Mesenchymal Stem Cells Clinical Trial
— CARE-SScOfficial title:
Phase I/II Randomized Controlled Trial of Umbilical Cord-derived mesenChymAl stRomal cElls in Systemic Sclerosis
The purpose of this study is to test the safety and efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (UCMSC) for the treatment of Systemic Sclerosis (SSc).
Status | Recruiting |
Enrollment | 18 |
Est. completion date | December 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. SSc according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2103 classification criteria for systemic sclerosis 2. Severe disease defined as: i) disease duration of 2 years or less with an mRss of > 20 and (ESR > 25 mm and/or hemoglobin < 11 g/dL, not explained by other causes than SSc), or ii) mRss >15 without any restriction as to disease duration plus at least one major organ involvement as defined by: a) respiratory involvement consisting of lung diffusion capacity for carbon monoxide (DLCO) and/or forced vital capacity (FVC) < 80% predicted and evidence of interstitial lung disease (chest X-ray and/or high resolution computed tomography (HRCT) scan); b) renal involvement consisting of past renal crisis and/or stage 2 or 3 chronic kidney disease (glomerular filtration rate between 30-89 mL/min) not explained by other causes than SSc; c) cardiac involvement consisting of reversible congestive heart failure, atrial or ventricular rhythm disturbances such as recurrent episodes of atrial fibrillation or flutter, recurrent atrial paroxysmal tachycardia, conduction abnormalities (2nd or 3rd degree atrioventricular block), and/or mild to moderate pericardial effusion. All causes of organ involvement should be attributed to SSc. 3. Inadequate response (determined by patient and physician judgement) or adverse events necessitating discontinuation of standard therapy (usually consisting of methotrexate 25 mg subcutaneous (or as tolerated) per week and/or mycophenolate mofetil 2-3 gm/d (or as tolerated) for at least 3 months 4. Ineligibility or unwillingness to undergo autologous hematopoietic stem cell transplant Exclusion Criteria: 1. Age < 18 years 2. Pregnancy or unwillingness to use adequate contraception 3. Life-threatening end-organ damage defined as: - FVC < 45% and/or DLCO (corrected for hemoglobin) < 30% predicted; - Left ventricular ejection fraction < 40% by cardiac echocardiography; - Pulmonary hypertension with baseline resting systolic pulmonary arterial pressures > 50 mmHg by cardiac echocardiography, or mean pulmonary artery pressure > 25 mmHg (and pulmonary wedge pressure < 15 mmHg) on right heart catheterization; - stage 4 or more chronic kidney disease (glomerular filtration rate < 30 ml/min) 4. Liver failure defined as an abnormal transaminase level (aspartate aminotransferase (ASAT), alanine aminotransaminase (ALAT) > 3 normal) unless related to activity of the disease 5. Concurrent neoplasms or myelodysplasia 6. Uncontrolled hypertension 7. Uncontrolled acute or chronic infection (HIV, HTLV-1/2 (Human T-lymphotropic virus), hepatitis B surface Ag positive, hepatitis C positive) or high risk thereof 8. Significant malnutrition with BMI < 18 kg/m2 9. Severe concomitant psychiatric disorder 10. Bone marrow insufficiency defined as neutropenia < 0.5 x 109 cell/L, thrombocytopenia < 30 x 109 cell/L, anemia < 8g/dL, CD4+ T lymphopenia < 200 x 106 cell/L due to other diseases than SSc (CD4 - cluster of differentiation 4) 11. History of poor compliance 12. Concurrent enrolment in any other protocol using an investigational drug 13. Inability to provide informed consent |
Country | Name | City | State |
---|---|---|---|
Canada | Sir Mortimer B. Davis Jewish General Hospital | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Marie Hudson, MD | Assistance Publique - Hôpitaux de Paris, Centre hospitalier de l'Université de Montréal (CHUM), McGill University Health Centre/Research Institute of the McGill University Health Centre, Medical University of South Carolina, Université de Montréal, University Paris 7 - Denis Diderot |
Canada,
Liang J, Zhang H, Kong W, Deng W, Wang D, Feng X, Zhao C, Hua B, Wang H, Sun L. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study. Stem Cell Res Ther. 2018 Nov 14;9(1):312. doi: 10.1186/s13287-018-1053-4. — View Citation
Wang D, Zhang H, Liang J, Wang H, Hua B, Feng X, Gilkeson GS, Farge D, Shi S, Sun L. A Long-Term Follow-Up Study of Allogeneic Mesenchymal Stem/Stromal Cell Transplantation in Patients with Drug-Resistant Systemic Lupus Erythematosus. Stem Cell Reports. 2018 Mar 13;10(3):933-941. doi: 10.1016/j.stemcr.2018.01.029. Epub 2018 Mar 1. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Safety at the time of infusion, 24 hours, 10 days +/- 24 hours, Month 6, Month 9 and Month 12 (adverse events) | Measure of safety of UCMSC in severe SSc using the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 classification [https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm] | 24 hours, 10 days +/- 24 hours, Month 6, Month 9 and Month 12 | |
Other | Mortality occurring after randomization and up to study completion | Causes of death and their relation to SSc versus the study intervention will be evaluated by the Data and Safety Monitoring Committee (DSMC). | 1 year | |
Other | Modified Rodnan skin score | A measure of skin thickness [Khanna et al., 2017] | Month 0, Month 3, Month 6 and Month 9 | |
Other | World Health Organization (WHO) performance status | WHO performance status [Oken et al., 1982] describes a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.). | Month 0, Month 3, Month 6, Month 9 and Month 12 | |
Other | Scleroderma-Health Assessment Questionnaire | Disease status as measured by the Scleroderma-Health Assessment Questionnaire [Steen & Medsger, 1997] | Month 0, Month 3, Month 6, Month 9 and Month 12 | |
Other | 36-Item Short Form Survey version 2 for health-related quality of life (SF-36v2) | Health-related quality of life as measured by the SF-36v2 [Ware et al., 2007] | Month 0, Month 3, Month 6, Month 9 and Month 12 | |
Other | EuroQoL health status measure (EQ-5D-5L) | Health related quality of life in cost effectiveness analysis as measured by the EQ-5D-5L [Herdman et al., 2011] using five levels of severity in five dimensions. | Month 0, Month 3, Month 6, Month 9 and Month 12 | |
Other | Response to treatment | Defined as decrease in mRss > 25%, increase in FVC > 10% predicted (forced vital capacity) and/or increase in DLCO >15% predicted (diffusing capacity of the lungs for carbon monoxide), without need for further immunosuppression except low dose steroids | Month 0, Month 12 | |
Other | Progression-free survival | Progression defined as any one of the following: decrease in FVC > 10% predicted; decrease in DLCO > 15% predicted; decrease in left ventricular ejection fraction on cardiac echocardiography > 15%; decrease in weight > 15%; decrease in creatinine clearance > 30%; increase in mRss > 25%; and/or increase in Scleroderma-Health Assessment Questionnaire > 0.5 | Month 0, Month 12 | |
Other | Global Rank Composite Score | A composite score consisting of a hierarchy of ordered outcomes: death, event-free survival (survival without respiratory, renal, or cardiac failure), FVC, score on the Disability Index of the Health Assessment Questionnaire (HAQ-DI; range, 0 to 3, with higher scores indicating more disability), and the modified Rodnan skin score. [Sullivan et al., 2018] | Month 0, Month 12 | |
Other | ACR Provisional Composite Response Index | ACR Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis (CRISS) [Khanna et al., 2016], a composite measure of treatment response in SSc | Month 0, Month 12 | |
Primary | Measure of safety one month after first infusion | Treatment related severe adverse event using the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 classification [https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm] | Month 1 | |
Secondary | Change in modified Rodnan skin score (mRss) between Month 0 and Month 12 | A measure of skin thickness; difference between Month 12 and Month 0 on the mRss [Khanna et al., 2017] | Month 0 and Month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01219465 -
Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes Mellitus
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01221428 -
Umbilical Cord Mesenchymal Stem Cells Infusion for Ulcerative Colitis
|
Phase 1/Phase 2 | |
Completed |
NCT03105284 -
Adipose-tissue Derived Stem Cells in Flaps Versus Liposuction
|
N/A | |
Not yet recruiting |
NCT01224327 -
Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT06149832 -
Treatment of Oral Chronic Graft-versus-host Disease With Human Umbilical Cord Mesenchymal Stem Cell Dressing
|
Phase 4 | |
Recruiting |
NCT05165459 -
Open Label Single Arm Proof of Concept Trial to Evaluate the Efficacy and Safety of Cytori Celution System in Chronic Non-Healing Venous Leg Ulcers
|
N/A | |
Active, not recruiting |
NCT04014166 -
Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia
|
N/A | |
Not yet recruiting |
NCT06077734 -
Muscle Stem Cell Quality in Atrophy
|
||
Completed |
NCT00956891 -
Therapeutic Effects of Liver Failure Patients Caused by Chronic Hepatitis B After Autologous MSCs Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT01218464 -
Safety and Efficacy of Human Mesenchymal Stem Cells for Treatment of Liver Failure
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03874572 -
Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth
|
Phase 1 | |
Recruiting |
NCT00953485 -
Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04863183 -
Cell Therapy With Cellistem-OA for Symptomatic Knee Osteoarthritis
|
Phase 1/Phase 2 | |
Completed |
NCT06360861 -
Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT05018754 -
Treatment of Oral Mucositis Using Platelet Rich Fibrin TREATMENT OF ORAL MUCOSITIS USING PRF
|
||
Completed |
NCT03130374 -
Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02673788 -
Follow-Up Study of Safety of Pneumostem® in Premature Infants With Intraventricular Hemorrhage
|
||
Recruiting |
NCT01763086 -
Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT01763099 -
Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure
|
Phase 2 | |
Completed |
NCT02302599 -
Mesenchymal Stem Cells to Treat Type 2 Diabetes
|
Phase 2 |